My watch list  


Cytochrome P450, family 2, subfamily C, polypeptide 9
Ribbon diagram of CYP2C9, heme group visible at center. From PDB 1OG2.
Available structures: 1og2, 1og5, 1r9o
Symbol(s) CYP2C9; CYP2C; CPC9; CYP2C10; MGC149605; MGC88320; P450 MP-4; P450 PB-1; P450IIC9
External IDs OMIM: 601130 MGI: 103238 Homologene: 86657
RNA expression pattern

More reference expression data

Human Mouse
Entrez 1559 13095
Ensembl ENSG00000138109 ENSMUSG00000003053
Uniprot P11712 Q3UEF2
Refseq NM_000771 (mRNA)
NP_000762 (protein)
NM_007815 (mRNA)
NP_031841 (protein)
Location Chr 10: 96.69 - 96.74 Mb Chr 19: 39.34 - 39.38 Mb
Pubmed search [1] [2]

Cytochrome P450 2C9 (abbreviated CYP2C9), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. It is involved in the metabolism of several important groups of drugs including many non-steroidal anti-inflammatory drugs (NSAIDs) and sulfonylureas.

Genetic polymorphism exists for CYP2C9 expression, with approximately 1–3% of Caucasian populations being poor metabolisers with no CYP2C9 function.


CYP2C9 Ligands

Selected inducers, inhibitors and substrates of CYP2C9[1]
Substrates Inhibitors Inducers
Often mentioned [2]:


Strong [3]:


Often mentioned [2]:


See also


  1. ^ Where classes of agents are listed, there may be exceptions within the class
  2. ^ a b Mentioned both in the reference named FASS and were previously mentioned in Wikipedia. Further contributions may follow other systems
  3. ^ Swedish environmental classification of pharmaceuticals Facts for prescribers (Fakta för förskrivare)

Further reading

  • Goldstein JA, de Morais SM (1995). "Biochemistry and molecular biology of the human CYP2C subfamily.". Pharmacogenetics 4 (6): 285-99. PMID 7704034.
  • Miners JO, Birkett DJ (1998). "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.". British journal of clinical pharmacology 45 (6): 525-38. PMID 9663807.
  • Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily.". Xenobiotica 28 (12): 1129-65. PMID 9890157.
  • Henderson RF (2001). "Species differences in the metabolism of olefins: implications for risk assessment.". Chem. Biol. Interact. 135-136: 53-64. PMID 11397381.
  • Xie HG, Prasad HC, Kim RB, Stein CM (2003). "CYP2C9 allelic variants: ethnic distribution and functional significance.". Adv. Drug Deliv. Rev. 54 (10): 1257-70. PMID 12406644.
  • Palkimas MP, Skinner HM, Gandhi PJ, Gardner AJ (2004). "Polymorphism induced sensitivity to warfarin: a review of the literature.". J. Thromb. Thrombolysis 15 (3): 205-12. doi:10.1023/ PMID 14739630.
  • Daly AK, Aithal GP (2004). "Genetic regulation of warfarin metabolism and response.". Seminars in vascular medicine 3 (3): 231-8. doi:10.1055/s-2003-44458. PMID 15199455.
  • García-Martín E, Martínez C, Ladero JM, Agúndez JA (2007). "Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.". Molecular diagnosis & therapy 10 (1): 29-40. PMID 16646575.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CYP2C9". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE